RICHARD KUNZ: Open Payments
NPI 1063147411 · NEW WINDSOR, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$959 in 52 payments from 10 companies in 2025. Trend: 2023 $466 · 2024 $820 · 2025 $959
Food & beverage: $959
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $315 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $156 |
| Alkermes, Inc. | 4 | $101 |
| E.R. Squibb & Sons, L.L.C. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| Tris Pharma Inc | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, COBENFY, REXULTI, LYBALVI, TRINTELLIX, FANAPT, Qelbree.
Industry payments across NY — which companies pay providers there.
